Shikari® Anti-Pertuzumab ELISA Kit

Anti-pertuzumab antibodies are a class of anti-drug antibodies (ADAs) that may be produced by the immune system in response to treatment with pertuzumab, a recombinant humanized monoclonal antibody targeting the HER2 receptor. Pertuzumab is used in combination with other agents such as trastuzumab and docetaxel for the treatment of HER2-positive metastatic breast cancer. While effective, pertuzumab, like other biologics, carries the potential to induce immunogenicity, leading to the formation of ADAs that may impact the drug’s efficacy and safety.

The development of anti-pertuzumab antibodies can alter pharmacokinetics, potentially reducing therapeutic drug levels or accelerating clearance from the body. In clinical settings, these antibodies may interfere with pertuzumab’s mechanism of action, especially if they are neutralizing. This interference can diminish the ability of pertuzumab to bind to the extracellular dimerization domain of the HER2 receptor, affecting its therapeutic outcomes. Consequently, monitoring for ADAs, including anti-pertuzumab antibodies, is a critical aspect of clinical trial development and therapeutic drug monitoring (TDM) in oncology.

In research and clinical practice, ADA monitoring assists in identifying patients who may be at risk of reduced response to therapy or adverse immune reactions. Therapeutic drug monitoring helps maintain effective serum levels of pertuzumab and supports individualized treatment regimens. These assessments contribute to understanding drug tolerability, patient compliance, and long-term treatment success, making anti-pertuzumab antibody evaluation an essential biomarker in personalized cancer care.

This product is manufactured in Turkey by Matriks Biotek.